Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 19/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018900 | 0.91 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL6963411 | 0.91 | CRHR1 (0.51) | CRHR1 | |
| SCHEMBL6968149 | 0.88 | CRHR1 (0.52) | CRHR1 | |
| SCHEMBL2019659 | 0.88 | CRHR1 (0.51) | CRHR1 | |
| SCHEMBL2016941 | 0.84 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL7077799 | 0.84 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL6965022 | 0.83 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL2017409 | 0.83 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL2019634 | 0.81 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL6968058 | 0.81 | CRHR1 (0.65) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | claimed |
| EP-0946520-B1 | ISOQUINOLINAMINE AND PHTHALAZINAMINE DERIVATIVES WHICH INTERACT WITH CRF RECEPTORS | NEUROGEN CORP (US) | 2003-04-02 | — | — | EP | claimed |
| US-6440969-B2 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-08-27 | — | — | US | claimed |
| US-6353103-B1 | STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY. | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | claimed |
| US-20010036945-A1 | Certain Isoquinolinamine and phthalazinamine derivatives; corticotropin-releasing factor receptor CRF1 specific ligands | NEUROGEN CORPORATION. | 2001-11-01 | — | — | US | claimed |
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
| EP-0946520-B1 | ISOQUINOLINAMINE AND PHTHALAZINAMINE DERIVATIVES WHICH INTERACT WITH CRF RECEPTORS | NEUROGEN CORP (US) | 2003-04-02 | — | — | EP | disclosed |
| US-6440969-B2 | PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-6353103-B1 | STRESS RELATED DISORDERS SUCH AS POST TRAUMATIC STRESS DISORDER (PTSD) AS WELL AS DEPRESSION, HEADACHE AND ANXIETY. | NEUROGEN CORPORATION | 2002-03-05 | — | — | US | disclosed |
| US-20010036945-A1 | Certain Isoquinolinamine and phthalazinamine derivatives; corticotropin-releasing factor receptor CRF1 specific ligands | NEUROGEN CORPORATION. | 2001-11-01 | — | — | US | disclosed |
| US-6235752-B1 | CORTICOTROPIN RELEASING FACTOR; PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-05-22 | — | — | US | disclosed |
| US-6114530-A | ISOQUIOLINAMINES AND PHTHALAZINAMINES USEFUL IN TREATING STRESS RELATED DISORDERES SUCH AS POST TRAUMATIC STRESS DISORDER AS WELL AS DEPRESSION, HEADACHE AND ANXIETY | NEUROGEN CORPORATION (US) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | MMP25, MMP9, MMP3 | CRHR1 2714/4885 |
| US-20010036945-A1 | Certain Isoquinolinamine and phthalazinamine derivatives; corticotropin-releasing factor receptor CRF1 specific ligands | CRHR1, CRH, CRHR2 | CRHR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.